Cerenis Therapeutics Announces Successful Completion of Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
TOULOUSE, France, & ANN ARBOR, Michigan, May 15, 2008 -
Cerenis Therapeutics SA (Cerenis), a privately held pharmaceutical
company developing HDL-related compounds for the treatment of
cardiovascular and metabolic diseases, today announced that it has
successfully completed a Phase I clinical trial for CER-002, one of
the company's lead product candidates.
CER-002 is a peroxisome proliferator-activated receptor (PPAR)
delta specific agonist in development for the treatment of
cardiovascular diseases. In the study, the product was found to
well tolerated and safe at all doses tested, without any serious
adverse effects. CER-002 is the most advanced small molecule HDL
candidate in Cerenis' portfolio. It was developed from new chemical
entities that are specific agonists for human PPAR delta, a
multifaceted therapeutic target with broad potential for the
treatment of cardiovascular and metabolic diseases. In preclinical
models, CER-002 has demonstrated strong efficacy in elevating HDL
and in halting the progression of atherosclerosis. It was selected
for clinical development from a series of small molecule compounds
available to Cerenis through a licensing agreement with Nippon
Chemiphar Co., Ltd.
"CER-002 is a novel compound which has shown significant
antiatherosclerotic properties in animal models even at low doses.
The completion of our first clinical trial represents an important
milestone for Cerenis, further validating our promising technology
platform and our expanding library of investigational compounds to
treat atherosclerosis. As we move forward with the clinical
development program for CER-002, we will also continue planning
clinical stage development programs for the other promising product
candidates in our portfolio," said Jean-Louis Dasseux, Ph.D.,
M.B.A., president and CEO of Cerenis.
The Phase I study for CER-002 was a randomized, double-blind,
placebo-controlled, cross-over, single-rising dose study conducted
with healthy male volunteers. Objectives of the study include
assessments of the safety, tolerability, and pharmacokinetics of
CER-002 when administered as a single dose, as well as the effect
of food on single dose pharmacokinetics. Twenty-four subjects
received CER-002.
About Cerenis Therapeutics Cerenis Therapeutics is a pharmaceutical
company focused on the discovery, development and commercialization
of breakthrough HDL-related therapies for the treatment of
cardiovascular and metabolic diseases. Based on pioneering research
conducted by the Cerenis team of world leaders in HDL therapy, the
company is pursuing a range of HDL product candidates that are
positioned to represent major advances in patient care and
significant commercial opportunities in the treatment of
cardiovascular and metabolic diseases. Cerenis has operations in
Ann Arbor, Michigan and Toulouse, France.
This email, its content and any files transmitted with it are
confidential and are intended only for the addressee. If you are
not the addressee, you may not print, copy, use or rely on the
contents, attachments or information in any way except with the
express written permission of the sender. If this email has been
sent to you in error please destroy it and contact the sender. This
email has been prepared using information believed by the author to
be reliable and accurate, but College Hill makes no warranty as to
its accuracy or completeness. In particular, College Hill does not
accept changes made to this email after it was sent.
Company Name: College Hill Associates Ltd, Company Number: 1036926 Registered Address: The Registry, Royal Mint Court, London EC3N 4QN UK
For further information please visit www.cerenis.com .
For more information, please contact: Europe: College Hill Tel.:
+44 (0)20 7866 7856 Holly Griffiths, Account Manager holly.griffiths@collegehill.com
Benjamyn Tan, Account Executive benjamyn.tan@collegehill.com
USA: Stephen Zoegall szoegall@berrypr.com Berry &
Company Public Relations Tel: +1 (212) 253-8881
Posted: May 2008
